Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 4/20 | 0.38 |
| ▸ | REN | P00797 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PEPD | P12955 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16327907 | 0.94 | ACE (0.42) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL4383861 | 0.94 | ACE (0.42) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL2482319 | 0.94 | ACE (0.42) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL12436085 | 0.85 | CHRM2 (0.45) | CA12CA1CA2CA9 | |
| SCHEMBL12719562 | 0.85 | CHRM2 (0.45) | CA12CA1CA2CA9 | |
| SCHEMBL25290224 | 0.85 | ATM (0.32) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL25290223 | 0.85 | ATM (0.32) | ACERENLMNAHSD17B10CYP2C19 | |
| SCHEMBL6478173 | 0.83 | ACE (0.50) | ACEREN | |
| SCHEMBL1950731 | 0.83 | ACE (0.50) | ACEREN | |
| SCHEMBL258790 | 0.83 | ACE (0.50) | ACEREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146703-A1 | SRC FAMILY KINASE INHIBITORS | Leo Pharma A/S (DK) | 2010-01-27 | — | — | EP | claimed |
| WO-2008128538-A1 | SRC FAMILY KINASE INHIBITORS | LEO PHARMA A/S (DK) | 2008-10-30 | — | — | WO | claimed |
| EP-4696312-A1 | ANTI-TROP2 ANTIBODY-NATURAL KILLER CELL CONJUGATE AND USE THEREOF | IMBIORAY (HANGZHOU) BIOMEDICINE CO., LTD. (CN) | 2026-02-18 | — | — | EP | disclosed |
| EP-4643889-A1 | ANTI-5T4 ANTIBODY-NATURAL KILLER CELL CONJUGATE AND USE THEREOF | IMBIORAY (HANGZHOU) BIOMEDICINE CO., LTD. (CN) | 2025-11-05 | — | — | EP | disclosed |
| EP-4643886-A1 | ANTI-CD33/CLL1 BISPECIFIC ANTIBODY-NATURAL KILLER CELL CONJUGATE AND USE THEREOF | IMBIORAY (HANGZHOU) BIOMEDICINE CO., LTD. (CN) | 2025-11-05 | — | — | EP | disclosed |
| EP-2220026-A2 | INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGENASE | Sterix Limited (GB) | 2010-08-25 | — | — | EP | disclosed |
| EP-2173745-A2 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | Array Biopharma, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| EP-2146703-A1 | SRC FAMILY KINASE INHIBITORS | Leo Pharma A/S (DK) | 2010-01-27 | — | — | EP | disclosed |
| EP-2084146-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Brystol-Myers Squibb Company (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2009073460-A2 | INHIBITION OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 FOR OCULAR NEUROPROTECTION | BAUSCH & LOMB INCORPORATED (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009066072-A2 | COMPOUND | STERIX LIMITED (GB) | 2009-05-28 | — | — | WO | disclosed |
| US-20040048852-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-03-11 | — | — | US | disclosed |
| US-6541489-B1 | Excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP- 1 | G. D. SEARLE & COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020177588-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2002-11-28 | — | — | US | disclosed |
| EP-1230219-A1 | AROMATIC SULFONS HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. Searle & Co. (US) | 2002-08-14 | — | — | EP | disclosed |
| US-20010039287-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | PHARMACIA CORPORATION | 2001-11-08 | — | — | US | disclosed |
| US-20010014688-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | BARTA THOMAS E (US) | 2001-08-16 | — | — | US | disclosed |
| EP-1042290-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000050396-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-08-31 | — | — | WO | disclosed |
| WO-1999025687-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177588-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP13, MMP9, MMP10 | CA12 224/4885CA1 172/4885CA2 211/4885 |
| US-20010039287-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | MMP13, MMP9, MMP10 | CA12 224/4885CA1 172/4885CA2 211/4885 |
| US-20040048852-A1 | Aromatic sulfone hydroxamic acid metalloprotease inhibitor | MMP9, MMP1, MMP13 | CA12 237/4885CA1 110/4885CA2 65/4885 |
| US-20010014688-A1 | AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | MMP13, MMP9, MMP10 | CA12 224/4885CA1 172/4885CA2 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.